Altium Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Altium Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,667	Closed	-$3.31M	–	140
2022 Q3	$3.31M	Hold	14,667	–	–	1.21%	34
2022 Q2	$2.77M	Hold	14,667	–	–	1.11%	34
2022 Q1	$3.65M	Buy	14,667 +5,967	+69%	+$943K	1.22%	35
2021 Q4	$1.35M	Buy	8,700 +2,117	+32%	+$409K	0.37%	82
2021 Q3	$1.32M	Hold	6,583	–	–	0.35%	86
2021 Q2	$1.68M	Hold	6,583	–	–	0.39%	90
2021 Q1	$1.75M	Hold	6,583	–	–	0.49%	87
2020 Q4	$2.43M	Buy	+6,583	New	+$1.89M	0.91%	47

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Altium Capital Management's EIGR Position: Q4 2022 in Review

Altium Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 14,667 shares — an estimated $3.31M sold.

Altium Capital Management first reported a position in EIGR in Q4 2020 and held it in 8 quarters. The position peaked at $3.65M in Q1 2022. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

Altium Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Altium Capital Management sold 14,667 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $3.31M.
Altium Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2020 and held it in 8 quarters.
Altium Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $3.65M in Q1 2022.
81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.